Convergent synthesis of ribonuclease L-active 2',5'-oligoadenylate-peptide nucleic acids

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 12, 2000, Pages 1357-1360

  Wang, Zhengfu ^a   Chen, Ling ^a   Bayly, Suzanne F ^a   Torrence, Paul F ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NORTHERN ARIZONA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 OLIGOADENYLATE NUCLEIC ACID; ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ADENINE NUCLEOTIDES; ENDORIBONUCLEASES; OLIGORIBONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS;

EID: 0034686432     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00240-7     Document Type: Article

References (28)

1. (a) Control of Messenger RNA Stability; Belasco, J.; Brawerman, G., Eds.; Academic: New York, NY, 1991.
2. (b) Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease; Torrence, P. F., Ed.; J. Wiley & Sons: New York, in press.
3. Ecker D.J., Griffey R.H. Drug Disc. Today. 4:1999;420.
4. Bennett C.F. Biochem. Pharmacol. 55:1998;9.
5. Crooke S.T. Antisense Nucleic Acid Drug Dev. 8:1998;vii-viii.
6. (a) Torrence, P. F.; Maitra, RK.; Lesiak, K.; Khamnei, S.; Zhou, A.; Silverman, R. H. Proc. Natl. Acad. Sci. USA 1993, 90, 1300.
7. (b) Lesiak, K.; Khamnei, S.; Torrence, P. F. Bioconjugate Chem. 1993, 4, 467.
8. (c) Maran, A.; Maitra, R. K.; Kumar, A.; Dong, B.; Xiao, W.; Li, G.; Williams, B. R.; Torrence, P. F.; Silverman, R. H. Science 1994, 265, 789.
9. (d) Cirino, N. M.; Li, G.; Xiao, W.; Torrence, P. F.; Silverman, R. H. Proc. Natl. Acad. Sci. USA 1997, 94, 1937.
10. (e) Player, M. R.; Barnard, D. L.; Torrence, P. F. Proc. Natl. Acad. Sci. USA 1998, 95, 8874.
11. (f) Maran, A.; Waller, C. F.; Paranjape, J. M.; Li, G.; Xiao, W.; Zhang, K.; Kalaycio, M. E.; Maitra, R. K.; Lichtin, A. E.; Brugger, W.; Torrence, P. F.; Silverman, R. H. Blood 1998, 92, 4336.
12. (g) Kondo, S.; Kondo, Y.; Li, G.; Silverman, R. H.; Cowell, J. K. Oncogene 1998, 16, 3323.
13. Player M.R., Torrence P.F. Pharmacol. Ther. 78:1998;55.
14. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. Science. 254:1991;1497.
15. Uhlmann E., Peyman A., Breipohl G., Will D.W. Angew. Chem., Int. Ed. Engl. 37:1998;2796.
16. Nielsen, P. E. In Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease, Torrence, P. F., Ed.; J. Wiley & Sons: New York, in press.
17. Verheijen J.C., van der Marel G.A., van Boom J.H., Bayly S.F., Player M.R., Torrence P.F. Bioorg. Med. Chem. 7:1999;449.
18. Imai J., Johnston M.I., Torrence P.F. J. Biol. Chem. 257:1982;12739.
19. Gite S., RajBhandary U.L. J. Biol. Chem. 272:1997;5305.
20. Wu T.P., Ruan K.C., Liu W.Y. Nucleic Acids Res. 24:1996;3472.
21. Proudnikov D., Mirzabekov A. Nucleic Acids Res. 24:1996;4535.
22. Bellon L., Workman C., Scherrer J., Usman N., Wincott F. J. Am. Chem. Soc. 118:1996;3771.
23. Summerton J., Weller D. Antisense Nucleic Acid Drug Dev. 7:1997;187.
24. Borch R.F., Bernstein M.D., Durst H.D. J. Am. Chem. Soc. 93:1971;2897.
25. 4 was from Sigma. BAP was from Sigma (P-4069, 100 units in 0.4 mL).
26. (a) Player, M. R.; Wondrak, E. M.; Bayly, S. F.;Torrence, P.F. Methods 1998, 15, 243.
27. (b) Silverman, R. H.; Krause, D. Lymphokines and Interferons: A Practical Approach; Clemens, M. J.; Morris, A. G.; Gearing, A. J. H., Eds.; 1987; p 149.
28. Torrence P.F., Imai J., Lesiak K., Jamoulle J.-C., Sawai H. J. Med. Chem. 27:1984;726.